What is Binimetinib?

Binimetinib (Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK1/2) inhibitor used in combination with conafenib (Encorafenib) for the treatment of certain patients with /span>Advanced melanoma (skin cancer) and non-small cell lung cancer (NSCLC) with mutations in the BRAF gene, which are detected in tumor specimens by a test approved by the U.S. Food and Drug Administration (FDA) before using bimetinib.

Bimetinib does not compete withATP and reversibly binds to and inhibits the activity of mitogen-activated extracellular signal-regulated kinase (MEK) 1 and 2. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, leading to the inhibition of growth factor-mediated cell signaling such as the downstream extracellular signal-related kinase (ERK) pathway. This may lead to inhibition of tumor cell proliferation and inhibition of the production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 itself is a threonine and tyrosine kinase with dual specificity. Subsequently, they play a key role in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in many different tumor cell types.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.